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doi:10.1Objective:Despite metallic and silicone stents being effective in treating various airway lesions, many concerns
still remain. A bioresorbable stent that scaffolds the airway lumen and dissolves after the remodeling process is
completed has advantages over metallic and silicone stents. We designed and fabricated a new mesh-type bio-
resorbable stent with a backbone of polycaprolactone (PCL), and evaluated its safety and biocompatibility in
a rabbit trachea model.
Methods: The PCL stent was fabricated by a laboratory-made microinjection molding machine. In vitro me-
chanical strength of the PCL stents was tested and compared to that of commercial silicone stents. The biore-
sorbable stents were surgically implanted into the cervical trachea of New Zealand white rabbits (n ¼ 6).
Animals received bronchoscopic examination at 1, 2, 4, 8, and 12 weeks after surgery. Histological examination
was completed to evaluate the biocompatibility of the stents.
Results: No animals died during the period of study. Distal stent migration was noted in 1 rabbit. In-stent se-
cretion accumulation was found in 2 rabbits. Histological examination showed intact ciliated epithelium and
marked leukocyte infiltration in the submucosa of the stented area at 10 and 28 weeks. Stent degradation was
minimal, and the mechanical strength was well preserved at the end of 33 weeks.
Conclusions: These preliminary findings showed good safety and biocompatibility of the new PCL stent when
used in the airway remodeling. PCL could be a promising bioresorbable material for stent design if prolonged
degradation time is required. (J Thorac Cardiovasc Surg 2011;141:463-8)G
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SAirway stents have been used widely for the treatment of tra-
cheobronchial stenosis, which is caused by malignant or
benign diseases such as intrinsic or extrinsic malignancies,
posttraumatic granulations, and/or tracheomalacia. Stenting
in the airway can provide the advantages of counteracting
scar contracture, promoting a scaffold for epithelium to cover
the reconstructed lumen of the airway, and preventing me-
chanical disruption secondary tomovement of the trachea dur-
ingbreathing and swallowing. Since the introduction ofT-tube
tracheal stent in 1965,1 silicone stents have been used in treat-
ing various airway diseases.2-5 However, due to the relatively
greater thickness and tubular geometry of the stents, the
mucociliary function of epithelium in the covered area can
be disturbed, resulting in impaired clearance of secretions
and luminal obstructions. Commonly seen complications of
silicone stenting include prosthesis migration, granulation
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The Journal of Thoracic and Caother hand, are thinner, more flexible, and easier to insert.
Because of their mesh-like design, the mucociliary function
of epithelium is well preserved, which leads to a better clear-
ance of secretions. Nevertheless, complications including
mucus plugging, stenosing granulation formation, tumor
in-growth, stent migration, stent fracture, and fistula between
the trachea and the brachiocephalic artery6-9 have been
reported. Furthermore, metallic stents are not amenable to
temporary intraluminal placement, once epithelization and
incorporation develop, they are difficult to remove. Airway
perforation can be a potential disaster during the removal of
metallic stents.
An ideal airway stent should reestablish the airway, cause
minimal morbidity and mortality, have limited migration
but be easily removed if necessary, maintain luminal pa-
tency without causing ischemia or erosion into adjacent
structures, cause minimal granulation tissue formation, be
easy to place, and be economically affordable.10 Stents
made of bioresorbable materials have advantages over sili-
cone and metallic stents in that they degrade with time and
removal of the stents is not necessary. This advantage is
even more pronounced in pediatric patients because as chil-
dren grow, the existing airway stents may need to be re-
moved or replaced by larger ones. Furthermore, a variety
of drugs can also be incorporated into bioresorbable stents
for controlled release and targeted local delivery, giving
them great potential for various clinical applications.
The purpose of this report is to develop bioresorbable
stents for airway remodeling. A balloon-expandable, mesh-
like stent with a backbone of polycaprolactone (PCL) wasrdiovascular Surgery c Volume 141, Number 2 463
Abbreviations and Acronyms
PCL ¼ polycaprolactone
PBS ¼ phosphate buffered saline
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Sfabricated by a laboratory-made microinjection molding
machine. The in vitro mechanical property of the bioresorb-
able stent was characterized, and the safety and biocompat-
ibility of the stent was evaluated in a rabbit trachea model.
The final goal of this research is to develop an absorbable
stenting system to provide an improved method for airway
remodeling.
MATERIALS AND METHODS
Materials
The polymer used for the fabrication of bioresorbable stents was poly-e-
caprolactone with a molecular weight of 80,000 (Sigma-Aldrich, St. Louis,
Mo). A DuPont model TA-2000 differential scanning calorimeter was used
to characterize the thermal properties of the polymer. The measured results
suggested that the melting temperature of the polymer was approximately
60.7C.
Fabrication of Bioresorbable Stents
The PCL stent was fabricated by a laboratory-made microinjection
molding machine.11 A mesh-type stent component, which consists of
ring-ellipse-ring units as shown in Figure 1, A, was first injection molded
by the machine. After molding, each stent component was interconnected
with another stent component. By interconnecting 7 components, the as-
sembly was rolled into a mesh tube and the final connecting points were
welded by hot spot welding. The fabricated stent was then passed over
a commercial balloon dilatation catheter (Coronary Stent Driver 3.00
mm3 12 mm; Medtronic, Inc, Galway, Ireland) for expansion. In the pro-
cess of balloon inflation, the rings slide over the central ellipse to the sides
resulting in expansion of the stent. With the release of balloon pressure,FIGURE 1. A, Dimensions of the stent component. B, F
464 The Journal of Thoracic and Cardiovascular Surga PCL stent with an axial length of 22 mm and final internal and external
diameters of 5 mm and 6 mm, respectively, was obtained. Figure 1, B,
shows the manufacture process of the biodegradable stents.
In Vitro Characterization of PCL Stents
To evaluate the mechanical properties, compression tests of bioabsorb-
able stents were carried out at room temperature. Area load was applied
over the full length of the stents with a 1500 mm2 plate mounted on
a LLOYD tensiometer. The cross-head speed was 1 mm/min. The deforma-
tion rate (DR%) of the stents is defined as:
DRð%Þ ¼ ½ðdiameter before loading diameter after loadingÞ
=ðdiameter before loadingÞ3 100 (1)
To compare the PCL stents manufactured in this study with the commercial
Dumon silicon stents (Novatech, Grasse, France), both PLC and commer-
cial silicon stents were compressed by a 1 Newton force and the deforma-
tion rates were recorded.
In vitro weight variation of PCL stents was monitored by immersing the
stents in a phosphate buffer, 0.15 mol/L (pH 7.4), at 37C. The samples re-
moved from the solutions at different weeks wereweighed after being dried
inside an oven for 24 hours. The weight retention (WR(%)) of the stents
was calculated according to the following equation:
WRð%Þ ¼ W
W0
3100 (2)
whereW0 andWwere the initial weight of the PCL stents and theweight of
the stents at different weeks, respectively. Furthermore, the deformation
rate of the eluted stents at different times was also measured by the com-
pression test described earlier.
In Vivo Study
Six New Zealand white rabbits with an average weight of 3.0 kg were
used in this study. During the surgical procedure, the animals were anesthe-
tized with an intramuscular injection of 1 ml 2% Rompun (Bayer Health-
Care, Animal Health Division, Leverkusen, Germany) and 1 ml Zoletil 50
(Virbac Laboratories, Carros, France). They maintained spontaneous
breathing without intubation. The cervical trachea was exposed. Aabrication process of the bioresorbable PCL stents.
ery c February 2011
Liu et al General Thoracic Surgerylongitudinal incision was made in midline of trachea, crossing six cartilage
rings starting from the third. The stent was implanted under direct vision.
The tracheotomy was then closed with 7-0 polypropylene suture. All ani-
mal procedures received institutional approval and all studied animals
were cared for in accordance with regulation of the National Institute of
Health of the Republic of China (Taiwan), under the supervision of a li-
censed veterinarian.
Animals received bronchoscopic examination at 1, 2, 4, 8, and 12
weeks. Three rabbits were killed by intravascular injection of lethal-dose
lidocaine at 10 weeks after stent implantation; two were killed at 28 weeks,
and the last at 33weeks. The cervical tracheawas excised and submitted for
histological examination. Mechanical properties (deformation rates) of the
stents retrieved from the animals at 28 and 33 weeks after implant were
tested and were compared to those of the in vitro ones.G
T
SRESULTS
In Vitro Evaluation of PCL Stent
Figure 2 shows the deformation of both PCL stents and
commercial silicone stents subjected to a 1 Newton load.
The experimental results suggest that the PCL stent ex-
hibited comparable mechanical strength with those of sili-
cone stents.
Figure 3, A, shows the weight retention of PCL stents
after immersion in PBS buffer for different times, whereas
Figure 3, B, shows the mechanical strengths of the eluted
stents. No significant mechanical strength and weight loss
of the stents was observed after being submerged in PBS
for 25 weeks. This might be due to the fact that the deg-
radation period of PCL materials is approximately 2
years.12 The degradation and the relevant strength reduc-
tion are thus negligible during a 25-week elution period.
Figure 3, A, also shows the compression strengths of
PCL stents being implanted in rabbits for 28 and 33
weeks. The measured results suggested that the deforma-
tion rate of bioresorbable stents decreased by 35% and
25% in vivo at 28 and 33 weeks, respectively, which im-FIGURE 2. A comparison of bioresorbable PCL stents and commercial
silicon stents.
The Journal of Thoracic and Caplies that the PCL materials become stiffer after being im-
planted in the trachea for some time.
In Vivo Animal Studies
No animal died of natural causes or airway complications
during the period of study. Intermittent stridor was noted at
times of agitation in 2 rabbits whose bronchoscopy showed
a moderate amount of airway secretion. The activity and ap-
petite of all animals were normal. Obvious weight gain was
noted during the period of study.
Figure 4 showed the bronchoscopic findings. Immedi-
ately after implantation, there was a small amount of blood
in the trachea lumen due to surgical bleeding. Subsequent
bronchoscopic pictures revealed excellent lumen patency,
with only minimal airway secretions in most of the animals
(n¼ 4).We did not observe stent fragmentation in any of the
animals.
Distal stent migration was noted in 1 rabbit (Figure 5, A),
which presumably resulted from forceful push by the rigid
bronchoscope at the first week. Gradual distal migration
was found in serial examinations. At 28 weeks, the distal
end of the stent was found at the carina. Moderate amount
of airway secretion was noted in 2 rabbits (Figure 5, B),
but it was not evident until 8 weeks after operation. In those
rabbits with moderate amount of airway secretion, intermit-
tent stridor was audible at times of agitation.
Histological Examination
At 10weeks after implantation, marked leukocyte infiltra-
tion in the submucosa of the stented area could be seen
(Figure 6, A). The ciliary structure of epithelium was main-
tained. Similar findingswere noted at 28weeks (Figure 6,B).
DISCUSSION
Bioresorbable materials have been used in humans as su-
ture and orthopedic or dental implants for several decades.
Not until the early 1990s did the clinical application
broaden to the field of stents. Until now, the applications
of bioresorbable airway stents have been largely experi-
mental.13-18 The first literature on a bioresorbable airway
stent was reported by Lochbihler13 in 1997. The authors de-
signed a bioresorbable stent consisting of polyglycolide
(PGA) filaments in a homogenous polydioxanone melt
and experimented in a rat trachea model. The stents began
to fragment after 4 weeks postimplantation and completely
resorbed after 8 weeks. Fourteen percent of the experimen-
tal animals died within the first week due to in-stent obstruc-
tive granulations.
Korpela14 described a new design of spiral stents made of
self-reinforced poly-L-lactide (PLLA), and compared with
silicone stents in a rabbit model of normal trachea. They
found that silicone stents had a tendency to become oc-
cluded with encrustation, whereas PLLA stents were well-
tolerated and caused no foreign body reaction. The PLLArdiovascular Surgery c Volume 141, Number 2 465
FIGURE 3. A, In vitro weight variation of PCL stents at different times. B, In vitro and in vivo deformation rates of PCL stents at different times.
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The authors then tested their stents in a rabbit model of tra-
chea stenosis, which was created by surgical resection of
cartilaginous arches of the cervical trachea.15 Similar con-
clusions were made: silicone stents had a tendency to oc-
clude because of internal encrustation and PLLA stents
were well-tolerated. Interestingly, one animal in the
PLLA stent group developed severe stridor at 26 weeks
postimplantation. Autopsy revealed fragments of the spirals
of the PLLA stent in the airway lumen. A similar finding
was noted in another rabbit that died 31 weeks postsurgery.
It was speculated that the PLLA stent fragments might have
caused airway obstruction, leading to the animal’s death.
Robey16 described their design of bioresorbable tracheal
stent, which was made of 80:20 poly (D,L-lactide-co-glyco-
lide) and was formed in a finger-type shape. In vitro results
of their study showed significant mass loss of the stents at 5
weeks, 50% mass loss at 10 weeks, and complete degrada-
tion at 14 weeks. They tested the stents in a rabbit tracheo-
malacia model, which was created by surgical
reconstruction of iatrogenic anterior tracheal wall defect
by homologous fascia lata grafts. The stented trachea had
a significantly smaller average stenosis (23%) across the
entire reconstruction site than the control group (34%)
(P<.05). Saito17 reported their experiment on bioresorb-
able PLLA stents. In contrast to previous studies, they de-
signed a tubular knitted stent and tested in a rabbit model
of normal trachea. At 40-weeks follow-up, all stents were
resorbed. No animals died of airway complications. The
new design of tubular knitted stent made possible a less-
invasive, endoscopic implantation. Later, Saito18 also suc-
cessfully deployed their PLLA stent in a dog model using
bronchoscope-guided, balloon expansion technique.
Among various bioresorbable materials, PGA, PLLA,
PCL, and their copolymers have gained considerable atten-466 The Journal of Thoracic and Cardiovascular Surgtion as the optimal biomaterials for stents. These polymers
differ in their chemical, physical, and biological character-
istics. They degrade in biological environments mainly by
hydrolysis of the ester linkages, and to a lesser extent by en-
zymatic digestion. Owing to the high degree of crystallinity
and hydrophobicity, the in vivo degradation time of PCL is
approximately 2 years.12 This characteristic offers a theoret-
ical advantage because the local remodeling process in pa-
tients with tracheal stenosis could take more than several
months. Biomaterials that degrade too quickly are not suit-
able for this clinical use.
PCL is nontoxic and tissue-compatible, and can be even-
tually resorbed in the vital organs. It is also a semicrystalline
polymer with a low melting point (59C to 64C), and ex-
hibits good flexibility at room temperature and at 37C as
compared to other biomaterials such as PLLA and PGA.19
This would avoid the occurrence of stent fragmentation15
that causes obstruction of the airway. The PLC stents are
still fairly flexible despite becoming stiffer in vivo at 33
weeks (Figure 3, B). Furthermore, stents with good flexibil-
ity are easier to be manipulated and deployed with minimal
invasion, and are more likely to adapt to the bifurcation
area.
Histological examination revealed significant inflamma-
tion in the stented area, which might contribute to the in-
creased airway secretion in some animals. Theoretically,
this problem could be alleviated by incorporation of anti-
inflammatory drugs in the stent. Furthermore, the mesh-
like design of PCL stents proposed in this study allowed
a bronchoscope-guided placement using the balloon expan-
sion technique. Note that the final step of fabrication of our
stent is expansion of the welded stent by an angiodilatation
balloon.
We note that in our animal model, the PCL stent was
tested with surgical insertion in 6 normal rabbits. Becauseery c February 2011
FIGURE 4. A, Immediate postoperative bronchoscopic picture showed blood in the trachea lumen; B, 1 week after surgery; C, 2 weeks after surgery; D, 4
weeks after surgery; E, 8 weeks after surgery; and F, 12 weeks after surgery.
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pipe, the stent may not behave the same when the underly-
ing airway is already injured. In addition, only 6 rabbits
were tested in our study. More animal tests would be neededFIGURE5. A,Distal stentmigration due to forceful push bybronchoscope at 1w
The Journal of Thoracic and Cato provide a better evaluation of the bioresorbable stents.
Further works with a larger number of animals using the
minimally invasive balloon-expansion deployment of bio-
resorbable stents will be the next step of our experiments.eek after surgery.B, In-stent secretion accumulation at 12weeks after surgery.
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FIGURE 6. A, At 10 weeks after surgery, histological examination showed marked leukocyte infiltration in the submucosa of stented area. B, Submucosa
leukocyte infiltration at 28 weeks after surgery.
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SCONCLUSIONS
This study has designed and fabricated a new bioresorb-
able stent with a backbone of PCL, and evaluates its safety
and biocompatibility in a rabbit trachea model. A mesh-like
PCL stent was fabricated by a lab-made micro injection-
molding machine and then expanded by a balloon to have
internal and external diameters of 5 and 6 mm, respectively.
The experimental results suggest that the PCL stent ex-
hibited comparable mechanical strength with those of com-
mercial silicone stents. Furthermore, the in vivo animal
study showed good safety and biocompatibility of the new
PCL stent when used in the airway remodeling. PCL could
be a promising bioresorbable material for stent design if the
desired degradation time is longer than 1 year.References
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